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Poster Session I 57post-HCT (10-pre-HCT and 5-post-HCT) comprising the Imati-
nib group and the remaining 17-patients, who either never received
Imatinib (n 5 13) or received it at time of relapse (n 5 4), were the
non-Imatinib group. Overall survival and relapse-free survival at 2
years was 73% and 65% for the Imatinib group compared to 34%
and 35% for the non-Imatinib group (p 5 0.14 and 0.1, respec-
tively). However, the incidence of relapse for these two groups
was 8% (95%CI: 0.00, 0.24) and 41% (95%CI: 0.17, 0.66), respec-
tively (p5 0.02). Transplant related mortality at 2-years was similar
between groups (27% and 24%; p5 0.81). Of note, cardiac toxicity
[defined as a reduction in left ventricular ejection fraction of.20%
below baseline, cardiac hypertrophy or EKG abnormalities (ST
changes, T-wave abnormalities, ischemia and/or infarction)] was
less in the Imatinib group, 23% (95% CI: 0.00, 0.49) versus 47%
(95% CI: 0.22, 0.72) (p 5 0.09). In conclusion, the use of Imatinib
therapy in patients with Ph1 ALL in either the pre-or-post-HCT
setting decreases the rate of relapse with a trend toward improved
RFS and OS. Furthermore, Imatinib treated patients have no obvi-
ous increased risk of cardiac toxicity.150
GENERATION OF AUTOLOGOUS LEUKEMIA-REACTIVE CYTOLYTIC T
CELLS (CTL) USING A NOVEL EXPANSION CULTURE SYSTEM: EFFECT
OF ANTI-CTLA-4 VERSUS IL-2
Zhong, R., Lane, T.A., Ball, E.D. University of California, San Diego
School of Medicine, La Jolla, CA.
Background: Evidence supports a role for immunotherapy in
acute myelogenous leukemia (AML). We previously reported
a novel method to generate autologous AML-reactive CTL from
the blood mononuclear cells (MNC) of pts with AML. The strategy
employs differentiation of AML blasts into dendritic cells (DC) fol-
lowed by expansion of autologous CTL. We further reported that
inclusion of anti-CTLA-4 in the culture system between days 1–8
augmented the cytotoxicity and interferon-g (IFN-g) release of
the expanded T cells (Cytotherapy 2006;8(1):3012). The purpose
of the current studies was to investigate whether similar augmenta-
tion of T cell function could be achieved by low dose IL-2 during
days 1–8 of culture. Methods: Primary AML peripheral blood or
marrow MNC were cultured in 96 well plates for 7 days in AIM-
V/RPMI-1640 with 10% AB serum, GM-CSF (50 ng/ml), IL-4
(1000 u/ml), and either anti-CTLA-4 (5 mcg/ml) or IL-2 (20 IU/
ml) from days 1–8 of culture, followed by T cell expansion using
OKT3 starting on day 14 and IL-2 (1000 U/ml) when T cells rep-
resented. 99% of all cells present, for up to 42 d. CTL activity was
assessed by lysis of 51-Cr labeled autologous AML-blasts and by
overnight generation of IFN-g. Results:Using this system we pre-
viously showed (n5 18) that CD331AMLblasts decreased from 80
6 28% preculture to\1% on d 35 while CD31 T cells increased
from 3% to . 99%. CTL produced 42 6 23% lysis of autologous
AML blasts at an Effector:Target (E:T) ratio 5 20:1 and was
blocked by anti-MHC class-I, but not MHC class II. CTL caused
\ 5% lysis of autologous PHA blasts and non-hematopoietic cells.
Incubation of CTL with autologous AML blasts decreased colony
growth .95% at E:T 5 2:1 (n 5 3). We now show, in cultures
from 7 different AML patients that the mean IFN-g generation us-
ing IL-2 during days 1–8 of culture was similar to that using anti-
CTLA-4 (2436 244 pg/ml vs 2546 335; p5 0.9) and in 2 studies
(12–24 replicates) that AML cell lysis using CTL generated with
IL-2 was similar to that with anti-CTLA-4 (30 6 13% vs 26 6
12; p5 0.2).Conclusion: A novel AML culture method employing
DC differentiation of AML cells followed by T cell expansion gen-
erated CTL that were highly reactive to autologous AML blasts. In-
clusion of low dose IL-2 early during culture was equally as effective
as anti-CTLA-4 in activating the CTL. This finding will facilitate
the design and conduct of immunotherapy trials of autologous ex-
panded CTL in patients with AML.151
MECHANISM OF BUSULFAN RESISTANCE OF MYELOID LEUKEMIA CELLS
Valdez, B.C.1, Murray, D.3, Ramdas, L.2, de Lima, M.1, Jones, R.1,
Kornblau, S.1, Betancourt, D.1, Li, Y.1, Champlin, R.E.1,Andersson, B.S.1 1UT MD Anderson Cancer Center, Houston, TX;
2UT MD Anderson Cancer Center, Houston, TX; 3Cross Cancer Insti-
tute, Edmonton, AB, Canada.
Busulfan (Bu) resistance is amajor obstacle to hematopoietic stem
cell transplantation (HSCT) of patients withmyelogenous leukemia
(CML and AML/MDS). To study cellular resistance phenomena
we established two Bu-resistant leukemia cell lines that were pheno-
typically characterized. The CML B5/Bu2506 cells are 4.5-fold
more resistant to Bu than their parental B5 cells. The AML
KBM3/Bu2506 cells are 4.0-fold more Bu-resistant than KBM3 pa-
rental cells.We then used gene expression analysis to identify differ-
entially expressed genes associated with Bu resistance. The results
suggest that Bu resistance is multifactorial and includes constitu-
tively up-regulated expression of genes involved in anti-apoptotis
(BCL-XL, BCL2, BCL2L10, BAG3 and IAP2/BIRC3), stress re-
sponse (HSP90 and STAT3), busulfan metabolism (GSTM), and
DNA repair (PARP1, ATM and Ku70/80). Furthermore, the Bu-re-
sistant sublines evade Bu-mediated G2-arrest and caspase-depen-
dent apoptosis. GSTM3 is up-regulated in KBM3/Bu2506 cells;
its ectopic expression in the KBM3 parental cell line imparts partial
resistance to Bu. Inhibitors of HSP90 activity, STAT3 phosphory-
lation and PARP1 functions were found to sensitize busulfan-resis-
tant cells. The role of DNA break repair on Bu resistance is
currently being investigated. Analysis of cells derived from patients
classified as either clinically resistant or sensitive to high-dose Bu-
based chemotherapy indicated alterations in gene expression that
were analogous to those observed in the in-vitro model cell lines,
confirming the clinical relevance of this model formechanistic stud-
ies of cellular Bu resistance.152
LONG TERM REMISSION IN PHILADELPHIA-POSITIVE ACUTE LYMPHO-
BLASTIC LEUKEMIA (Ph1 ALL) PATIENTS AFTER ALLOGENEIC MYE-
LOABLATIVE HEMATOPOIETIC CELL TRANSPLANTATION (HCT) USING
MATCHED RELATED DONORS: THE 20 YEAR EXPERIENCE AT STANFORD
UNIVERSITY AND CITY OF HOPE NATIONAL MEDICAL CENTER
Laport, G.G.1, Alvarnas, J.C.2, Palmer, J.M.2, Snyder, D.S.2,
Slovak, M.L.2, Cherry, A.M.1, Negrin, R.S.1, Blume, K.G.1,
Forman, S.J.2 1Stanford University Medical Center, Stanford, CA;
2City of Hope National Medical Center, Duarte, CA.
Due to the inherently poor prognoses of patients with Philadel-
phia-positive ALL, allogeneic HCT is offered early in their treat-
ment course if a suitable donor is available. We report the 20 year
experience from 1985 to 2005 at Stanford University and City of
Hope National Medical Center in which 79 patients with matched
related donors received a myeloablative conditioning regimen. The
median age of all patients (pts) was 36 years (range 2–57 years). At
the time of HCT, forty-nine pts (62%) were in first complete remis-
sion (CR1) and 30 pts (38%) were beyond CR1 (.CR1). The ma-
jority of pts (85%) received the conditioning regimen of
fractionated total body irradiation (FTBI, dose 5 1320 cGy) and
high dose VP16 (60 mg/kg), 11 (14%) patients received FTBI/
VP16/cyclophosphamide and one patient received the FTBI/V16/
busulfan regimen (1%). The most commonly used graft vs host dis-
ease (GVHD) prophylaxis regimens were cyclosporine (CSA) and
methotrexate (47%) and CSA/methotrexate/methylprednisolone
(29%). The 10-year outcomes are listed in the table below. At diag-
nosis, forty percent of pts had chromosomal abnormalities in addi-
tion to t(9;22) but this was not found to affect survival outcomes.
Pre-HCT factors that significantly affected event free survival
(EFS) and overall survival (OS) were WBC at diagnosis (\30,000
vs $30,000) and disease status (CR1 vs .CR1). The development
of grade 2–4 acute GVHD was an adverse factor for DFS and OS
by both univariate and multivariate analysis. Factors significantly
associated with increased nonrelapse mortality (NRM) were a his-
tory of radiation therapy prior to HCT for extramedullary disease
and disease status with the .CR1 pts experiencing a significantly
higher NRM. The inferior EFS and OS for the .CR1 pts was at-
tributed to the higher NRM. The median time to relapse for the
CR1 patients was 12 months (range, 1–27 months) and for the
.1CR patients was 9 months (range, 3–19 months) indicating
